Navigation Links
Psychemedics Corporation Announces First Quarter Results
Date:4/30/2008

Increases Quarterly Dividend

ACTON, Mass., April 30 /PRNewswire-FirstCall/ -- Psychemedics Corporation (Amex: PMD) today announced first quarter financial results for the period ended March 31, 2008. The Company also announced a quarterly dividend of $0.17 per share payable to shareholders of record as of June 6, 2008 to be paid on June 20, 2008. This will be the Company's 47th consecutive quarterly dividend.

The Company's revenue for the quarter ended March 31, 2008 was $5.7 million essentially matching revenue for the quarter ended March 31, 2007. Net income for the quarter ended March 31, 2008 was $0.9 million or $0.17 per share, a decrease of 14% from the comparable period last year during which the Company earned $1.0 million or $0.20 per share.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said, "Despite the challenging economy which saw significant job losses for the first quarter 2008, our revenue remained the same at $5.7 million for the first quarter of 2008 when compared to the first quarter of 2007. Even with the absorption of normal cost increases, our gross margins improved to 58%, up from 57% in the first quarter of 2007, although revenues remained flat."

Kubacki continued, "Our net income was below historic levels due in part to our recent investment in our sales and marketing team during the first quarter of 2008. We expect that the addition of our Director of Marketing and our lead generation team should provide the Company with the tools to capitalize on significant growth opportunities."

Kubacki concluded, "The Company's balance sheet remains strong with approximately $9.1 million of cash and short-term investments, no long-term debt and over $12.7 million of working capital at March 31, 2008. The 13% dividend increase from $0.15 to $0.17 demonstrates our directors' commitment to rewarding shareholders and sharing the financial success of the Company. Therefore we are pleased to declare our 47th consecutive quarterly dividend."

On March 17, 2008, the Company announced the authorization of a 250,000 share stock repurchase program.

Psychemedics is the world's largest provider of hair testing for drugs of abuse with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.

Financial Highlights:

-- Revenue for the first quarter of $5.7 million, no significant change

from 2007

-- Pretax income for the first quarter of $1.5 million, down 13% from 2007

-- Net income for the first quarter of $0.9, or $0.17 per diluted share,

down 14% from 2007

The Psychemedics web site is http://www.drugtestwithhair.com

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, growth opportunities, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing team, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.

Contact:

Jennifer Chmieleski

Vice President and Controller

(978) 206-8220

Jenniferc@psychemedics.com

PSYCHEMEDICS CORPORATION

STATEMENTS OF INCOME

(in thousands, except per share amounts)

UNAUDITED

Three months ended

March 31, March 31,

2008 2007

REVENUE $5,709 $5,717

COST OF REVENUE 2,387 2,455

Gross profit 3,322 3,262

OPERATING EXPENSES:

General and administrative 1,022 832

Marketing and selling 799 705

Research and development 118 95

1,939 1,632

Income from operations 1,383 1,630

Interest income 112 96

INCOME BEFORE PROVISION FOR INCOME TAXES 1,495 1,726

PROVISION FOR INCOME TAXES 605 691

NET INCOME $890 $1,035

BASIC NET INCOME PER SHARE $0.17 $0.20

DILUTED NET INCOME PER SHARE $0.17 $0.20

DIVIDENDS DECLARED PER SHARE $0.15 $0.125

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING,

BASIC 5,221 5,179

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING,

DILUTED 5,309 5,265

PSYCHEMEDICS CORPORATION

BALANCE SHEETS

(in thousands, except per share amounts)

March 31, December 31,

2008 2007

(Unaudited)

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $6,310 $6,097

Short-term investments 2,800 3,875

Accounts receivable, net of allowance for

doubtful accounts of $235 3,570 3,555

Prepaid expenses and other current assets 1,142 499

Deferred tax assets 457 429

Total current assets 14,279 14,455

PROPERTY AND EQUIPMENT:

Equipment and leasehold improvements,

at cost 10,821 10,793

Less - Accumulated depreciation and

amortization (10,062) (9,977)

759 816

DEFERRED TAX ASSETS 231 231

OTHER ASSETS 62 59

$15,331 $15,561

LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $337 $489

Accrued expenses 1,013 951

Deferred revenue 212 243

Total current liabilities 1,562 1,683

SHAREHOLDERS' EQUITY:

Preferred stock, $0.005 par value;

873 shares authorized and none

outstanding - -

Common stock, $0.005 par value;

50,000 shares authorized,

5,815 shares issued in 2008 and 5,812

shares issued in 2007 29 29

Paid-in capital 26,660 26,540

Accumulated deficit (3,422) (3,527)

Less - Treasury stock, at cost;

607 shares in 2008 and 586 shares

in 2007 (9,498) (9,164)

Total shareholders' equity 13,769 13,878

$15,331 $15,561


'/>"/>
SOURCE Psychemedics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue
2. Jennifer Chmieleski Joins Psychemedics Corporation as Top Financial Officer
3. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
4. Nihon LocalSoft Designs New Japanese Software for IRadimed Corporations Award-Winning MRidium MRI Infusion System
5. BioElectronics Corporation Announces New Website for Italian Market
6. DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference Call
7. Digirad Corporation and University of Chicago Medical Center Sign Letter of Agreement
8. HTG-Ventrex, Signalifes Contract Manufacturer, Acquired by Parker Hannifin Corporation
9. Torchmark Corporation Declares Dividend
10. Steris Corporation Announces the Appointment of Two New Directors
11. Digirad Corporation Reports Financial Results for First-Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 05, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Tasting Event at the La Gorce Country Club in Miami Beach on March ...
(Date:2/5/2016)... ... 2016 , ... Regular gym users know the routine: each January, they see ... the treadmills. It’s a predictable trend. After the excesses of November and December, people ... by joining gyms, starting new walking or running routines, or signing up for Zumba. ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... (APDA) announced the election of Patrick McDermott as Chairman of the National Board of ... welcome Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... Move from on one drop zone to the next using Colorize's dynamic moving camera. ... any project. This package includes a 3D slideshow environment with 1 to 5 focus ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... for Patients with Rare Diseases, a continuing medical education (CME) event presented by ... first of its kind—and a first for ACCORD, whose mission is to provide ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... , Feb. 4, 2016 Summary ... common cancer and the most common cancer in women ... the disease exceedingly prevalent. The number of women diagnosed ... decades, but the number of deaths has declined due ... cancer treatment has been revolutionized in the past four ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
Breaking Medicine Technology: